Keytruda's revenue continues to climb, reaching over $15 billion in the first half of 2025, while Merck's HPV vaccine sales decline in 2025

Worldwide revenue (in USD) for the second quarter (Q2) of 2025, the first half (H1) of 2025, and 2024 for Merck & Co.'s (MSD) marketed drugs.

(Please use a modern browser to see the interactive version of this visualization)

Chart: © Phalguni Deswal, Drug and Device World (www.druganddeviceworld.com)Source: MSD financial disclosuresDownload imageCreated with Datawrapper